| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/BF01745246 |
| P698 | PubMed publication ID | 7962984 |
| P2093 | author name string | F Sörgel | |
| M Kinzig | |||
| P2860 | cites work | Efficacy and safety of aminoglycosides once-a-day: experimental and clinical data | Q33728949 |
| Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate | Q35343060 | ||
| Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli | Q35650267 | ||
| Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery | Q35900491 | ||
| Human pharmacodynamics of beta-lactams, aminoglycosides and their combination | Q37803195 | ||
| Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli | Q39815796 | ||
| Piperacillin Sodium: Antibacterial Spectrum, Pharmacokinetics, Clinical Efficacy, and Adverse Reactions | Q40114428 | ||
| Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. | Q40196652 | ||
| Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases | Q40283720 | ||
| Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin | Q40284229 | ||
| The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam | Q40852062 | ||
| Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease | Q67485735 | ||
| Piperacillin/tazobactam in the treatment of serious acute soft tissue infection | Q68256495 | ||
| Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads | Q70148102 | ||
| P921 | main subject | pharmacokinetics | Q323936 |
| piperacillin/tazobactam | Q7197337 | ||
| P304 | page(s) | S14-20 | |
| P577 | publication date | 1994-07-01 | |
| P1433 | published in | Intensive Care Medicine | Q15749164 |
| P1476 | title | Pharmacokinetic characteristics of piperacillin/tazobactam | |
| P478 | volume | 20 Suppl 3 |
| Q35132672 | Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa. |
| Q36496470 | Empirical antibiotic treatment with piperacillin-tazobactam in patients with microbiologically-documented biliary tract infections. |
| Q33559047 | Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. |
| Q34381321 | Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens |
| Q41706103 | Pharmacokinetics of drugs used in critically ill adults |
| Q36364174 | Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile |
| Q89982258 | Unorthodox Parenteral β-lactam and β-lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care |
Search more.